Harrow (HROW)
Commercializes branded eye medicines and ImprimisRx compounding for US ophthalmology.
$33.86
vs last close−0.59 (−1.71%)
Something off on this page? Send us feedback.
13F · 13D/G · Form 4
| Institutions | 58.09% | 21.78M shares | |
|---|---|---|---|
| 234 holders · as of Jun 30, 2026 | |||
| Insiders | 20.32% | 7.62M shares | |
| 6 holders · as of May 19, 2026 | |||
| Other | 21.59% | 8.10M shares | |
| remainder | |||
37.49M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
13F, as of Jun 30, 2026
234 holders · 21.78M shares · 43 new positions · 121 increased · 67 reduced · 37 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 2.74M | 7.31% | +187.4K | Aug 7, 2026 |
| Opaleye Management Inc. | 2.40M | 6.40% | −432.2K | Aug 14, 2026 |
| Private Capital Management, LLC | 1.60M | 4.26% | +36.8K | Aug 14, 2026 |
| Vanguard Capital Management LLC | 1.42M | 3.78% | +14.2K | Aug 13, 2026 |
| Deep Track Capital, LP | 969.0K | 2.58% | +969.0Knew | Aug 14, 2026 |
| State Street Corp | 939.9K | 2.51% | +84.8K | Aug 7, 2026 |
| Geode Capital Management, LLC | 905.6K | 2.42% | +53.5K | Aug 12, 2026 |
| Bamco Inc /NY/ | 809.4K | 2.16% | +809.4Knew | Aug 14, 2026 |
13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Mark L. Baum | 10.69% | 4.06M | 13D | Apr 7, 2025 |
| Opaleye Management Inc. | 7.61% | 2.83M | 13G | May 11, 2026 |
| Daniel Kaufman | 5.04% | 1.88M | 13G | Mar 11, 2026 |
Form 4
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Aug 14, 2026 | Amir Shojaeiofficer: CHIEF SCIENTIFIC OFFICER | Sale | 11,250 | $40.00 | 0 |
| May 18, 2026 | Lauren P. Silvernaildirector | Purchase | 1,000 | $31.00 | 1,000 |
| May 18, 2026 | Adrienne L. Gravesdirector | Purchase | 1,000 | $31.07 | 1,000 |
| May 14, 2026 | Andrew R. Bollofficer: PRESIDENT AND CFO | Purchase | 3,500 | $29.90 | 814,679 |
| May 14, 2026 | Mark L. Baumdirector, officer: CHIEF EXECUTIVE OFFICER | Purchase | 10,000 | $30.20 | 2,996,130 |
| Mar 4, 2026 | Opaleye Management Inc.10 percent owner | Sale · 2 lots | 138,263 | $39.67 | 59,428 |
| Mar 3, 2026 | Opaleye Management Inc.10 percent owner | Sale · 2 lots | 60,309 | $39.15 | 63,691 |
| Feb 27, 2026 | Opaleye Management Inc.10 percent owner | Sale | 5,000 | $54.18 | 65,000 |
| Jan 6, 2026 | Opaleye Management Inc.10 percent owner | Sale | 20,000 | $53.35 | 70,000 |
House and Senate disclosures
Not reported.